Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PRAX-222 - Fixed Doses

PreclinicalSmall molecule

PPraxis Precision Medicines

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

SCN2A-DEEActive, not recruiting

SCN2A-DEEPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q1 2028

PreclinicalActive, not recruiting

SCN2A-DEE

NCT05737784

Clinical

Trials by Indication[1]

SCN2A-DEE1 trial

A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Active, not recruiting·PPraxis Precision Medicines·Preclinical·NCT05737784·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PRAX-222 - Fixed Doses. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRAX-222 - Fixed Doses compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRAX-222 - Fixed Doses. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Praxis Precision Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPraxis Precision Medicines

Related News